Literature DB >> 20571266

Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases.

Chuntao Gao1, Xiuqing Fu, Yi Pan, Qiang Li.   

Abstract

OBJECTIVES: To review the clinical data of a group of patients with pancreatic neuroendocrine tumors (pNETs) and to investigate the role of surgery in the treatment for pNETs by analyzing clinical manifestations and postoperative course of this rare disease.
METHODS: A total of 112 patients (aged 21-76 years; 45 males) who underwent treatment between 1980 and 2003 were recruited in this study. Patients' data related to demographics and characteristics, diagnostic studies, surgical and tumor characteristics and survival were retrospectively reviewed.
RESULTS: Forty-six patients (41.1%) had a well-differentiated neuroendocrine tumor (WDT), 44 (48.2%) a well-differentiated neuroendocrine carcinoma (WD-Ca) and 12 (10.7%) a poorly differentiated neuroendocrine carcinoma (PD-Ca). Nonfunctional tumors were seen in 65 (58.0%) patients, whereas functional tumors were found in 47 (42.0%) patients, including 26 insulinomas, 17 gastrinomas, 2 VIPomas, 1 glucagonoma, and 1 ACTHoma. The sensitivity of computed tomography was 87.1%. Surgical resection was performed in 99 (88.4%) patients. Thirty-eight (33.9%) patients underwent partial pancreaticoduodenectomy, 32 (28.6%) had distal pancreatectomy and 29 (25.9%) underwent enucleation. No surgery-related death occurred. The common postoperative complications were pancreatic fistula (15.2%), wound infection (13.4%) and delayed gastric emptying (6.3%). Three (5%) patients had reoperation due to intra-abdominal abscess and postoperative hemorrhage. Twenty-six (55.3%) of the 47 functional tumors were malignant, whereas 40 (61.5%) of the 65 nonfunctional tumors were malignant. Survival was significantly related to the type of neuroendocrine tumor (p = 0.001). The overall 5-year actual survival rate of patients with WD-Ca (n = 54) was 56%, significantly less than that of patients with WDT (n = 46, 91%, p = 0.001). All the patients of PD-Ca (n = 12) group died in 5 years. The 5-year survival rate differed significantly between patients with tumor node metastasis (TNM) stage I and II disease and those with stage III and IV tumors (p = 0.011). Patients with stage III had better prognosis than those with stage IV tumors (p = 0.007). Patients' long-term survival was closely correlated with vascular invasion (p = 0.008) and resection margin (p = 0.004).
CONCLUSIONS: PNETs can be safely resected. Microscopic vascular invasion and positive resection margin are helpful for predicting patient survival. Malignant cases should be treated with aggressive radical surgery to achieve complete tumor resection and potential for long-term survival.

Entities:  

Mesh:

Year:  2010        PMID: 20571266     DOI: 10.1159/000253871

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  8 in total

1.  Bone lesions in recurrent glucagonoma: A case report and review of literature.

Authors:  Cristian Ghetie; Daniel Cornfeld; Vassilios S Ramfidis; Kostas N Syrigos; Muhammad W Saif
Journal:  World J Gastrointest Oncol       Date:  2012-06-15

2.  A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.

Authors:  Mohammad Y Zaidi; Alexandra G Lopez-Aguiar; Jeffrey M Switchenko; Joseph Lipscomb; Valentina Andreasi; Stefano Partelli; Adriana C Gamboa; Rachel M Lee; George A Poultsides; Mary Dillhoff; Flavio G Rocha; Kamran Idrees; Clifford S Cho; Sharon M Weber; Ryan C Fields; Charles A Staley; Massimo Falconi; Shishir K Maithel
Journal:  Ann Surg       Date:  2019-09       Impact factor: 12.969

3.  Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series.

Authors:  Resit Demir; Johann Pohl; Abbas Agaimy; Georgios Peros; Aristoteles Perrakis; Susanne Merkel; Werner Hohenberger; Peter Klein
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 4.  Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.

Authors:  Paige Finkelstein; Rishika Sharma; Omar Picado; Rahul Gadde; Heather Stuart; Caroline Ripat; Alan S Livingstone; Danny Sleeman; Nipun Merchant; Danny Yakoub
Journal:  J Gastrointest Surg       Date:  2017-03-02       Impact factor: 3.452

5.  Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas.

Authors:  De-shen Wang; Dong-sheng Zhang; Miao-zhen Qiu; Zhi-qiang Wang; Hui-yan Luo; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  Tumour Biol       Date:  2011-04-09

6.  A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.

Authors:  Yong Gao; Hao Gao; Guangfu Wang; Lingdi Yin; Wenbin Xu; Yunpeng Peng; Junli Wu; Kuirong Jiang; Yi Miao
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

7.  Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: A case report.

Authors:  Xuefeng Cao; Xixiu Wang; Yanmin Lu; Baolei Zhao; Jian Shi; Qinghai Guan; Xingyuan Zhang
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

8.  Somatostatin Receptor Scintigraphy Findings in a Patient with Metastatic Gastrinoma and MEN 1 Syndrome.

Authors:  Gözde Mütevelizade; Mehmet Aydın; Ahmet Sezer
Journal:  Mol Imaging Radionucl Ther       Date:  2011-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.